Compare Five Below Inc (FIVE) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Inovio Pharmaceuticals Inc — how do they compare? Five Below Inc trades at $209.85 (market cap $11.55B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M). The key difference: Five Below Inc is far larger — about 103× Inovio Pharmaceuticals Inc's market cap, and Five Below Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FIVE | INO | |
|---|---|---|
Market Cap | $11.55B | $112.19M |
Volume | 1,120,554 | 3,201,278 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $2.65 |
52-Week Low | $138.49 | $0.66 |
Typical Hold Time | 46 Days | 43 Days |
Enterprise Value | $12.40B | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $204.24, down 2.71% today, with strong analyst support (60% buy ratings) and a consensus price target of $298.44. The stock shows robust fundamentals with revenue growth from $3.6B in 2024 to $3.9B in 2025 and projected $5.3B in 2026, alongside consistent earnings beats. Technical indicators are mixed with a bearish overall signal but bullish oscillators, while recent news highlights digital marketing initiatives and board appointments.
FIVE presents a compelling growth story with raised 2026 guidance and strong profitability metrics (ROE 28.25%), though premium valuation (P/E 18.81) and execution risks amid consumer spending pressures warrant caution. Upside potential exists if traffic and margin trends sustain, but investors should monitor inflation impacts on discretionary retail spending.
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
